What benefits are associated with GP IIb/IIIa platelet receptor inhibitors for patients with diabetes mellitus?
A meta-analysis of the effect of GP IIb/IIIa platelet receptor inhibitors (abciximab, eptifibatide, and tirofiban) on mortality in NSTEMI revealed that for the entire patient group, a GP IIb/IIIa inhibitor was associated with a reduction in mortality. This benefit was particularly large in the 1279 patients with diabetes mellitus who underwent PCI (4.0% to 1.2%; P=0.002).